oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Oral Semaglutide Reduces Cardiovascular Events in People SELECT Trial

Lower Inflammation This one's huge

Genetic data should complement clinical evaluation, not replace it

Research Applications GH Axis Research: Comprehensive dual-pathway growth hormone secretion studies

By Lana Pine | Published on February 12, 2025 5 min read Over nine weeks, individuals who took once-weekly low-dose semaglutide a glucagon-like peptide 1 (GLP-1) receptor agonist often used for diabetes and weight loss drank less alcohol in a lab test, had lower alcohol cravings and smoked fewer cigarettes (if they were smokers)

US Endocrinol

This hormone helps regulate blood sugar, slows down digestion, and tells your brain that you are full